SCHEMBL23728153

SCHEMBL23728153

CCCCCC=CCCCCCCCCCCC=CC(=O)N1CCCCC1

nearest known ligand 0.97

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GMNN O75496 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C9 P11712 1/20 0.46
ALOX15 P16050 1/20 0.46
APEX1 P27695 1/20 0.46
CYP2C19 P33261 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46
DUSP3 P51452 1/20 0.46
MMP2 P08253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23728151 1.00 MEN1 (0.49) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL10337271 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL692004 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL692068 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL10337272 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL30636021 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL692069 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL13090346 0.98 L3MBTL1 (0.50) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL691996 0.97 L3MBTL1 (0.49) MEN1KMT2ATDP1L3MBTL1GMNN
SCHEMBL691997 0.97 L3MBTL1 (0.49) MEN1KMT2ATDP1L3MBTL1GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115515614-A Compositions comprising extracts of alpinia and other plants for improving joint health and treating arthritis 尤尼根公司 2022-12-23 CN disclosed
EP-4100034-A1 COMPOSITIONS COMPRISING EXTRACTS OF APLINIA AND OTHER PLANTS FOR IMPROVING JOINT HEALTH AND TREATING ARTHRITIS Unigen, Inc. (US) 2022-12-14 EP disclosed
US-20220000964-A1 Compositions and Methods for Regulating Homeostasis of Chondrocytes, Extracellular Matrix, Articular Cartilage, and Phenotype of Arthritis UNIGEN, INC. (US) 2022-01-06 US disclosed
WO-2021159042-A1 COMPOSITIONS COMPRISING EXTRACTS OF APLINIA AND OTHER PLANTS FOR IMPROVING JOINT HEALTH AND TREATING ARTHRITIS UNIGEN, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000964-A1 Compositions and Methods for Regulating Homeostasis of Chondrocytes, Extracellular Matrix, Articular Cartilage, and Phenotype of Arthritis COL2A1, COL1A1, CKAP4 MEN1 2515/4885KMT2A 1517/4885TDP1 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.